{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-113954","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.358148+00:00","generated_at":"2026-06-03T08:03:19.489050+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares","bullets":["90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.","Exchange closed April 25, 2024; common shares outstanding post-exchange: 40,279,414.","Exemption from registration relied on Section 3(a)(9) of Securities Act; no commission paid.","Counterparty is Fairmount Healthcare Fund II L.P.; conversion ratio based on existing conversion terms.","Following exchange, 346,045 Series A Preferred and 271,625 Series B Preferred remain outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-113954","json":"https://secwatch.observer/filing/0001193125-24-113954.json","markdown":"https://secwatch.observer/filing/0001193125-24-113954.md","text":"https://secwatch.observer/filing/0001193125-24-113954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/0001193125-24-113954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524113954/d787764d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T08:03:19.489050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}